RxDoctor Payments Data

Faith Marie Oakley, NP

Gerontology · North Wilkesboro, NCNPI 1336658392

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $767, 4.6 times the $168 reported in 2023.

$1,456in general payments, 2019–2025

Across 74 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$262
  • GSK$203
  • Novo Nordisk$166
  • Otsuka America Pharmaceutical, Inc.$150
  • Pfizer$89
  • Eisai Inc.$88
  • plus $497 from 13 others

What the payments were for

  • Food & beverage$1,456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,456 in reported general payments places this provider in the 80th percentile of 165 gerontology providers in North Carolina.

See all gerontology providers in North Carolina

Medicare billing

Part B allowed, 2024
$62,281
Medicare patients
218
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$39,829
MounjaroTirzepatide31$39,478
EliquisApixaban39$38,803
TrulicityDulaglutide16$33,904
JardianceEmpagliflozin12$17,098
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,222
XareltoRivaroxaban12$12,664
Tresiba Flextouch U-200Insulin Degludec12$10,174
SymbicortBudesonide/Formoterol Fumarate16$5,682
Advair HfaFluticasone Propion/Salmeterol16$5,580
Serevent DiskusSalmeterol Xinafoate12$5,116
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,054
Albuterol Sulfate HfaAlbuterol Sulfate86$2,386
Arnuity ElliptaFluticasone Furoate11$2,265
Rosuvastatin Calcium217$1,967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$85$73,38247 claims
Novo NordiskOzempic$166$39,82924 claims
PfizerEliquis$89$38,80339 claims
GSKTrelegy Ellipta, Arnuity Ellipta$203$15,48728 claims
AstraZenecaSymbicort$262$5,68216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 gerontology providers in North Carolina.

Other gerontology in North Wilkesboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →